Appletreeclinics Network Sp. z o.o.

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)5 trials
• COPD1 trial
• Migraine1 trial
• Psoriasis1 trial
• Ulcerative colitis1 trial

Phase

• Phase 35 trials
• Phase 24 trials

Status

• Completed7 trials
• Active, not recruiting2 trials

Lead sponsor

• Amgen Inc.2 trials
• Sun Pharmaceutical Industries Limited2 trials
• Abivax1 trial
• Amgen1 trial
• H. Lundbeck A/S1 trial
• and 2 more

Running trials

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

  NCT05878769· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis

  2023-507974-42-00· Phase 2· Abivax· Source

Closed trials

• Completed

  A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

  NCT06323928· Phase 2· H. Lundbeck A/S· Source

• Completed

  Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO)

  2022-501586-50-00· Phase 3· Amgen Inc.· Source

• Completed

  A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon)

  2022-501538-44-00· Phase 3· Amgen Inc.· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Completed

  To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis

  NCT04684485· Phase 2· Sun Pharmaceutical Industries Limited· Source

• Completed

  To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis

  NCT04566666· Phase 2· Sun Pharmaceutical Industries Limited· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source